New HIV drug candidate targets resistant strains
NCT ID NCT07711210
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This study tests a new drug called ACC017 in adults with HIV that has become resistant to standard treatments. The trial aims to see if ACC017 can lower the amount of virus in the blood to undetectable levels. Participants receive either ACC017 or a placebo for two weeks, followed by an open-label phase where everyone gets ACC017 with an optimized background regimen.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ACC017 tablets
- What this could lead to
- If successful, ACC017 could offer a new treatment option for people with HIV that has stopped responding to standard non-nucleoside reverse transcriptase inhibitors (NNRTIs).
- What could go wrong
- This is an early-stage trial with only 12 participants, so results may not apply to everyone. The drug may not effectively suppress the virus or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTION, HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Clinical Center for Public Health
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.